Glucotrack

Executive Summary

Glucotrack is a medical technology company developing a fully implantable continuous blood glucose monitoring (CBGM) system aimed at eliminating external wearables for people with diabetes. By measuring glucose directly from the blood, the device seeks to reduce management burden and environmental waste from disposable sensors. Founded in 2002 and headquartered in Fort Lauderdale, Florida, the company is advancing its proprietary technology through pre-clinical studies, positioning itself to address key limitations of current continuous glucose monitors (CGMs), such as sensor lifespan, accuracy, and user convenience. Currently in the pre-clinical stage, Glucotrack is progressing toward first-in-human studies, with the goal of demonstrating the safety and efficacy of its implantable sensor. If successful, the system could disrupt the diabetes monitoring market by offering a longer-lasting, maintenance-free alternative to traditional CGMs. However, the company faces significant regulatory hurdles and competition from established players. The upcoming clinical milestones and potential strategic partnerships will be critical for de-risking the technology and attracting investment. Glucotrack's novel approach represents a paradigm shift in diabetes care, pending successful validation.

Upcoming Catalysts (preview)

• H2 2026Initiation of First-in-Human Clinical Trial70% success
• Q3 2026Presentation of Preclinical Study Results80% success
• Q4 2026Strategic Partnership or Licensing Agreement50% success